z-logo
Premium
Genetic variations in SLC3A2/CD98 gene as prognosis predictors in non‐small cell lung cancer
Author(s) -
Guo Xu,
Li Hongwei,
Fei Fei,
Liu Boya,
Li Xiaofei,
Yang Hushan,
Chen Zhinan,
Xing Jinliang
Publication year - 2015
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.22167
Subject(s) - biology , single nucleotide polymorphism , hazard ratio , oncology , lung cancer , genotype , medicine , genotyping , confidence interval , snp , proportional hazards model , multivariate analysis , bioinformatics , genetics , gene
Non‐small cell lung cancer (NSCLC) is characterized by poor prognosis and only a few molecular markers may be potentially used to predict the risk of progression. This study aims to assess the effects of single nucleotide polymorphisms (SNPs) in the CD98 gene on prognosis of NSCLC patients. We genotyped three potential functional SNPs in CD98 gene using Sequenom iPLEX genotyping system in a cohort of 482 NSCLC patients. Multivariate cox proportional hazards model and Kaplan–Meier curve were used for the survival analysis. The variant‐containing genotypes of rs1059292 in 5′‐flanking region of CD98 gene were significantly associated with an increased risk of death in the multivariate analysis (Hazard ratio [HR], 1.49; 95% confidence interval [95% CI]: 1.04–2.14 in a dominant model). In stratified analysis, the association remained significant in patients with poor differentiation (HR = 1.81, 95% CI = 1.01–3.25). In addition, rs1059292 also showed a borderline significant association with T stage (OR = 1.49; 95% CI: 0.96–2.35) and N stage (OR = 1.53; 95% CI: 0.98–2.39). Functional analysis demonstrated that variant genotype of SNP rs1059292 significantly enhanced the transcription activity of CD98 gene promoter. Our data suggest that genetic variation of rs1059292 in CD98 gene may affect clinical outcome of NSCLC in Chinese population. © 2014 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here